Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · CORONA

CORONA

HealthcarePharmaceuticals & Biotechnology₹13805 cr market cap
₹2237.80 ▼ -0.82% today As of 19 Nov 2026
52-week low ₹1347.7052-week high ₹2539.40

-11.2% from the 52-week high · +67.4% above the low

Corona Remedies Ltd is a pharmaceutical company focused on branded formulations. It develops and markets prescription medicines across multiple therapeutic areas. The company emphasizes physician engagement and strong brand recall in chronic therapies. Its operations are supported by in-house manufacturing and quality control systems. Corona Remedies primarily serves the Indian healthcare market.

The short version. CORONA reported revenue of ₹441 crore for Sep 2026, up 22.2% from a year earlier. Net profit was ₹60 crore (up 15.4% year on year). Return on equity was 24.8% in Mar 2026. Promoter holding was 69.0% in Sep 2026, up 0.00 points over 5 quarters.

1 · The price

How has the stock traded?

CORONA trades 11.2% below its 52-week high and 67.4% above its 52-week low.

Change over period: —

1M+12.2%
3M+6.4%
6M+30.3%
1Y—

2 · The business

Is it growing?

Sales, year on year+22.2%

Sep 2026 revenue of ₹441 cr.

Profit, year on year+15.4%

Sep 2026 net profit of ₹60 cr.

Net margin13.7%

0.8 pts lower than a year earlier.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025
Revenue441422353342361
Net profit6060454152
Net margin %13.714.212.812.114.5
EPS (₹)9.869.837.416.758.55

Annual

FY2026
Revenue1403
Net profit185
Net margin %13.2
EPS (₹)30.27

3 · The quality

How well does it turn capital into profit?

Return on equity was 24.8% in Mar 2026; debt to equity is 0.19.

Profitability · 1 years

Returns and margins

Mar 2026
Return on equity %24.8
Return on capital %29.3
EBITDA margin %20.2
Net margin %13.1

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR——
Profit CAGR——
Debt to equity0.19
Interest cover35.5x
Current ratio0.96
P/E ratio66.9

4 · The owners

Who holds it, and are they adding?

Promoter holding69.0%

Unchanged over 5 quarters.

Foreign institutions4.21%

Up 3.17 pts over 5 quarters.

Domestic institutions16.45%

Up 12.8 pts over 5 quarters.

Mutual fund schemes44

+14 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter69.069.069.069.069.00.0
FII1.041.842.253.634.21+3.17
DII3.656.767.0212.916.45+12.8
Public26.3222.421.7414.4810.34-15.98

Mutual fund holdings · Oct 2026

44 schemes hold this stock

30 the month before.

  • Invesco India Pharma and Healthcare Fund5.76% of NAV
  • Invesco India Consumption Fund3.29% of NAV
  • UNION SMALL CAP FUND2.61% of NAV
  • SBI Healthcare Opportunities Fund2.41% of NAV
  • SBI Dividend Yield Fund2.37% of NAV
  • ADITYA BIRLA SUN LIFE PHARMA & HEALTHCARE FUND2.31% of NAV
  • WhiteOak Capital Pharma and Healthcare Fund2.3% of NAV
  • SBI Long Term Advantage Fund - Series VI2.27% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for CORONA are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about CORONA

What is the CORONA share price?

CORONA (CORONA) last closed at ₹2,237.80, down 0.82% on the day. Its 52-week range is ₹1,347.70 to ₹2,539.40.

What is the market cap of CORONA?

CORONA has a market capitalisation of about ₹13,805 crore. Its price-to-earnings ratio is 66.9.

How are CORONA's latest results?

CORONA reported revenue of ₹441 crore for Sep 2026, up 22.2% from a year earlier. Net profit was ₹60 crore (up 15.4% year on year). Return on equity was 24.8% in Mar 2026. Promoter holding was 69.0% in Sep 2026, up 0.00 points over 5 quarters.

Who owns CORONA?

As of Sep 2026, shareholding was: Promoter 69.0%, FII 4.21%, DII 16.45%, Public 10.34%.

How many mutual funds hold CORONA?

44 mutual fund schemes held CORONA in October 2026. That compares with 30 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 19 Jun 2026 · Final Dividend - Rs. 10

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.